Change in composition of the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 16 May 2017 - Novo Nordisk today announced that Mary Szela steps down from Novo Nordisk's board of directors with immediate effect. The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest.
"I acknowledge and support Ms Szela's decision to step down from the Board of Directors and I would like to thank Ms Szela for her valuable contribution since joining in March 2015," said Göran Ando, chairman of the Board of Directors at Novo Nordisk.
|Anne Margrethe Hauge||+45 3079 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 786 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Hanna Ögren||+45 3079 email@example.com|
|Anders Mikkelsen||+45 3079 firstname.lastname@example.org|
|Kasper Veje (US)||+1 609 235 email@example.com|
Company announcement No 37 / 2017